Amarin (AMRN) Projected to Post Earnings on Wednesday

Amarin (NASDAQ:AMRN - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect Amarin to post earnings of ($0.06) per share and revenue of $50.75 million for the quarter.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($1.20). The company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Stock Performance

Shares of AMRN traded down $0.30 during trading hours on Monday, reaching $10.61. 53,936 shares of the company traded hands, compared to its average volume of 73,910. Amarin has a 1-year low of $7.08 and a 1-year high of $20.60. The stock's fifty day moving average is $9.51 and its 200 day moving average is $10.34. The stock has a market cap of $219.72 million, a P/E ratio of -117.91 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. The Goldman Sachs Group reduced their price objective on shares of Amarin from $20.00 to $7.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. StockNews.com initiated coverage on shares of Amarin in a research report on Wednesday, April 16th. They set a "sell" rating on the stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.